Vaxcyte

Vaxcyte company information, Employees & Contact Information

Explore related pages

Related company profiles:

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice. We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Company Details

Employees
492
Founded
-
Address
825 Industrial Rd,
Phone
(650) 837-0111
Email
in****@****yte.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Carlos, California
Looking for a particular Vaxcyte employee's phone or email?

Vaxcyte Questions

News

Vaxcyte to Establish Fill-Finish Manufacturing in North - GlobeNewswire

Vaxcyte to Establish Fill-Finish Manufacturing in North GlobeNewswire

$1 Billion Manufacturing Deal: Vaxcyte Brings Vaccine Production to US with Thermo Fisher Partnership - Stock Titan

$1 Billion Manufacturing Deal: Vaxcyte Brings Vaccine Production to US with Thermo Fisher Partnership Stock Titan

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - GlobeNewswire

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) GlobeNewswire

Vaxcyte's VAX-31 Vaccine Gets FDA Green Light for Phase 3 Launch: $2.8B War Chest Powers Clinical Progress - Stock Titan

Vaxcyte's VAX-31 Vaccine Gets FDA Green Light for Phase 3 Launch: $2.8B War Chest Powers Clinical Progress Stock Titan

Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease - Quiver Quantitative

Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease Quiver Quantitative

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update Yahoo Finance

92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants - Stock Titan

92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants Stock Titan

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - Stock Titan

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors Stock Titan

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewswire

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study GlobeNewswire

Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial - Stock Titan

Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial Stock Titan

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - GlobeNewswire

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study GlobeNewswire

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs - GlobeNewswire

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs GlobeNewswire

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older - Yahoo Finance

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Yahoo Finance

Addition of Lauryldimethylamine N-Oxide (LDAO) to a Copper-Free Click Chemistry Reaction Improves the Conjugation Efficiency of a Cell-Free Generated CRM197 Variant to Clinically Important Streptococcus pneumoniae Serotypes - ACS Publications

Addition of Lauryldimethylamine N-Oxide (LDAO) to a Copper-Free Click Chemistry Reaction Improves the Conjugation Efficiency of a Cell-Free Generated CRM197 Variant to Clinically Important Streptococcus pneumoniae Serotypes ACS Publications

FDA clears investigational NDA for VAX-31 to prevent invasive pneumococcal disease - Contemporary Pediatrics

FDA clears investigational NDA for VAX-31 to prevent invasive pneumococcal disease Contemporary Pediatrics

Vaxcyte Announces Pricing of $1.3 Billion Public Offering - GlobeNewswire

Vaxcyte Announces Pricing of $1.3 Billion Public Offering GlobeNewswire

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial - The Lancet

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial The Lancet

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates - Yahoo Finance

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates Yahoo Finance

Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc. - The Business Journals

Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc. The Business Journals

Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis - The Lancet

Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis The Lancet

The changing landscape of adult pneumococcal vaccines - Healio

The changing landscape of adult pneumococcal vaccines Healio

Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation - Medical Professionals Reference

Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation Medical Professionals Reference

24-Valent Pneumococcal Conjugate Vaccine Shows Strong Immune Response in Infants - Drug Topics

24-Valent Pneumococcal Conjugate Vaccine Shows Strong Immune Response in Infants Drug Topics

SutroVax Announces Name Change to Vaxcyte - GlobeNewswire

SutroVax Announces Name Change to Vaxcyte GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies - GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

Top Vaxcyte Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant